Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nanoparticles as adjuvants for vaccines

J Kreuter1

  • 1Institute for Pharmaceutical Technology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.

Pharmaceutical Biotechnology
|January 1, 1995
PubMed
Summary

Polymethyl methacrylate (PMMA) nanoparticles effectively enhance immune responses and antibody production against various antigens. These safe, reproducible nanoparticles show promise as vaccine adjuvants, improving immunogen stability and protection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 'HLA conundrum in bone marrow transplantation': correct interpretation of anti-HLA antibodies in haploidentical donor selection.

Bone marrow transplantation·2017
Same author

Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer.

Journal of controlled release : official journal of the Controlled Release Society·2015
Same author

Arylsulfatase A bound to poly(butyl cyanoacrylate) nanoparticles for enzyme replacement therapy--physicochemical evaluation.

Die Pharmazie·2014
Same author

Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI.

Die Pharmazie·2013
Same author

Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects.

Clinical neuropathology·2009
Same author

Antiparkinsonian effect of nerve growth factor adsorbed on polybutylcyanoacrylate nanoparticles coated with polysorbate-80.

Bulletin of experimental biology and medicine·2008

Area of Science:

  • Immunology and Vaccinology
  • Nanotechnology in Medicine
  • Biomaterials Science

Background:

  • Adjuvants are crucial for enhancing vaccine efficacy.
  • Nanoparticle-based adjuvants offer potential for improved immunogenicity and stability.
  • Polymethyl methacrylate (PMMA) is a biocompatible polymer with potential as a vaccine carrier.

Purpose of the Study:

  • To evaluate polymethyl methacrylate (PMMA) nanoparticles as vaccine adjuvants.
  • To assess the impact of PMMA nanoparticles on antibody responses and immunogen stability.
  • To investigate the safety and efficacy of PMMA nanoparticles in preclinical models.

Main Methods:

  • Physicochemically reproducible manufacturing of PMMA nanoparticles with controlled particle size.
  • Incorporation or adsorption of various immunogens (influenza virions/subunits, BSA, HIV vaccines) onto PMMA nanoparticles.
  • Evaluation of antibody responses, immunogen stability, and protective immunity against influenza challenge.

Main Results:

  • PMMA nanoparticles induced significantly higher and more prolonged antibody responses against diverse immunogens.
  • Enhanced immunogen stability and protective immunity against live influenza virus challenge were observed.
  • PMMA did not induce antibodies against gp120 in HIV-2 vaccine, suggesting antigen-specific adjuvant requirements.

Conclusions:

  • PMMA nanoparticles are effective, safe, and reproducible vaccine adjuvants.
  • Combination adjuvant strategies may be necessary for complex antigen mixtures.
  • PMMA warrants further investigation as a versatile vaccine adjuvant material.

Related Experiment Videos